Skip to content

Released Nov 11, 2021, after the close

10-Q filed Nov 12, 2021, 43 days after period end · 0001390478-21-000036

Q3 2021 · 10-Q
Revenue$0.00— vs Q3 2020−100.0% vs Q2 2021
Net Income-$7.09MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.45N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$6,977,000N/M
Operating Cash Flowderived-$5,878,000N/M

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$0.00$0.00——
Net Income-$7.09M-$4.47M-$4.20M-$290.00K
EPS Diluted-$0.45-$0.53-$2.68-$26.75

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR